OncoSignal
Live from Open Targets Platform, fetched 2026-11-12 01:05 UTC. Every row links to its source record.

BRCA2 BRCA2 DNA repair associated

ENSG00000139618 · protein coding · Open Targets profile

Tumor suppressor protein that maintains genome stability primarily by repairing damaged DNA through homologous recombination (HR) (PubMed:11239456, PubMed:12442171, PubMed:15115758, PubMed:15199141, PubMed:15671039, PubMed:15937124, PubMed:17515903, PubMed:17515904, PubMed:18317453, PubMed:19303847, PubMed:20729832, PubMed:20729858, PubMed:20729859, PubMed:21719596, PubMed:27941124, PubMed:37499663, PubMed:37515771). Facilitates the repair of double- strand breaks (DSBs) by binding and mediating the loading of the RAD51 protein onto single-stranded DNA (ssDNA), thereby promoting the activity of RAD51, which catalyzes DNA strand exchange (PubMed:11239456, PubMed:12442171, PubMed:15937124, PubMed:17515903, PubMed:17515904, PubMed:18317453, PubMed:19303847, PubMed:20729832, PubMed:20729858, PubMed:20729859, PubMed:27941124, PubMed:37499663). BRCA2 nucleates and stabilizes RAD51 on ssDNA directly and delivers RAD51 to ssDNA-double-stranded DNA (dsDNA) junctions by sliding along dsDNA backbone (PubMed:12442171, PubMed:19303847, PubMed:37499663). RAD51 targeting to ssDNA promotes removal of replication protein-A (RPA) from ssDNA and stabilization of RAD51-ssDNA filaments by blocking ATP hydrolysis (PubMed:20729859). May play a role in the extension step after strand invasion at replication-dependent DNA double-strand breaks; together with PALB2 is involved in both POLH localization at collapsed replication forks and DNA polymerization activity (PubMed:24485656). Required to prevent R-loop-associated DNA damage and thus transcription-associated genomic instability (PubMed:24896180). Silencing of BRCA2 promotes R-loop accumulation at actively transcribed genes in replicating and non-replicating cells, suggesting that BRCA2 mediates the control of R-loop associated genomic instability, independently of its known role in homologous recombination (PubMed:24896180). Also promotes RAD51 loading to telomeric regions, facilitating telomere replication and capping (PubMed:21076401). Also required for homologous recombination during meiosis by promoting the recruitment of RAD51 and DMC1 recombinases to meiotic DSB sites, enabling proper chromosome pairing and crossing over (PubMed:26976601). Also promotes homologous recombination by inactivating the FIGNL1-FIRRM complex to protect RAD51 filament from premature disassembly (PubMed:37515771). Together with NPM1, may also regulate centrosome duplication (PubMed:21084279). {ECO:0000269|PubMed:11239456, ECO:0000269|PubMed:12442171, ECO:0000269|PubMed:15115758, ECO:0000269|PubMed:15199141, ECO:0000269|PubMed:15671039, ECO:0000269|PubMed:15937124, ECO:0000269|PubMed:17515903, ECO:0000269|PubMed:17515904, ECO:0000269|PubMed:18317453, ECO:0000269|PubMed:19303847, ECO:0000269|PubMed:20729832, ECO:0000269|PubMed:20729858, ECO:0000269|PubMed:20729859, ECO:0000269|PubMed:21076401, ECO:0000269|PubMed:21084279, ECO:0000269|PubMed:21719596, ECO:0000269|PubMed:24485656, ECO:0000269|PubMed:24896180, ECO:0000269|PubMed:26976601, ECO:0000269|PubMed:27941124, ECO:0000269|PubMed:37499663, ECO:0000269|PubMed:37515771}.

In 15 of 15 cancers, the evidence for BRCA2 comes mainly from inherited variants

Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.

Inherited (germline) variantsMutations in tumours (somatic)
00.250.50.751breast cancerbreast cancerbreast cancer: germline 0.98breast neoplasmbreast neoplasmbreast neoplasm: somatic 0.86breast neoplasm: germline 0.95breast carcinomabreast carcinomabreast carcinoma: somatic 0.53breast carcinoma: germline 0.95breast-ovarian cancer, familial, suscep…breast-ovarian cancer, familial, susceptibility to, 2breast-ovarian cancer, familial, susceptibility to, 2: somatic 0.95breast-ovarian cancer, familial, susceptibility to, 2: germline 0.97ovarian neoplasmovarian neoplasmovarian neoplasm: somatic 0.75ovarian neoplasm: germline 0.88hereditary breast ovarian cancer syndro…hereditary breast ovarian cancer syndromehereditary breast ovarian cancer syndrome: germline 0.88ovarian cancerovarian cancerovarian cancer: somatic 0.86ovarian cancer: germline 0.95hereditary breast carcinomahereditary breast carcinomahereditary breast carcinoma: somatic 0.55hereditary breast carcinoma: germline 0.95medulloblastomamedulloblastomamedulloblastoma: somatic 0.23medulloblastoma: germline 0.94prostate cancerprostate cancerprostate cancer: germline 0.83prostate carcinomaprostate carcinomaprostate carcinoma: somatic 0.61prostate carcinoma: germline 0.77glioma susceptibility 3glioma susceptibility 3glioma susceptibility 3: germline 0.94Familial prostate cancerFamilial prostate cancerFamilial prostate cancer: germline 0.94Wilms tumor 1Wilms tumor 1Wilms tumor 1: germline 0.94BRCA2-related cancer predispositionBRCA2-related cancer predispositionBRCA2-related cancer predisposition: germline 0.97

Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.

Tractability

Small molecule
Structure with Ligand
PROTAC
UniProt Ubiquitination, Database Ubiquitination

gnomAD loss of function constraint: o/e 0.7335799932479858 (upper bound 0.8240900039672852). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.

Who runs trials of these drugs

No named investigators on registry trials of BRCA2's approved or late-stage drugs in the last three years.

No terminated, withdrawn or suspended trials of BRCA2's drugs are registered

All 0 drugs and clinical candidates as a table

Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.

DrugTypeHighest stageIndicationsSource records
No drugs or clinical candidates recorded.